To explore the potential application of capsid-targeted viral inactivation (CTVI) strategy in prophylactic model against dengue virus (DV) infection, here we fused a Ca 2+ -dependent nuclease, staphylococcal nuclease (SN), to the capsid protein of dengue 2 virus (D2C) at the carboxyl terminal, and constructed the desired expression plasmid pc/D2C-SN and control plasmids pc/D2C-SN* and pc/D2C. A mammalian cell line BHK-21 was transfected by electroporation with those plasmids and thereafter selected by 5 µg/ml blasticidin. The resistant cell clones were then expanding cultured and screened by RT-PCR and Western Blot assays. The nuclease activity of the expressed fusion protein D2C-SN was analyzed by in vitro DNA digestion assay. It was confirmed cell lines stably expressing D2C-SN and control constructs were obtained. The intracellular expressed fusion protein D2C-SN had ideal nuclease activity and no cytotoxicity on mammalian cells. Those engineered cell lines provided the experimental system for CTVI application in prophylactic model and paved the new road for combating DV infection with CTVI.
Dengue virus (DV) is one of the most significant human viral pathogens transmitted by arthropod vectors and now present in over 100 countries. Half of the world's population live in areas at risk of dengue virus infection [1] . The infection of DV causes a spectrum of diseases ranging from a debilitating, self-limited illness (dengue fever), and life-threaten syndromes (dengue haemorrhagic fever/dengue shock syndrome). Annually, the four serotypes of DV collectively cause 50-100 million cases of infection worldwide, resulting in around 25,000 deaths [2] . In spite of efforts to develop live attenuated, inactivated or recombinant subunit vaccines for decades, currently, no effective and safe vaccine against DV is commercially available, no specific drugs against DV exist and few antiviral drugs have been tested [3] , and supportive care and symptomatic treatment are the only measures to improve survivals if DHF/DSS develops during the course of DV infection.
Capsid targeted viral inactivation (CTVI) is a novel intracellular immunization approach for viral infection, which can introduce deleterious enzymes, such as nuclease, into outgoing viral particles during assembly by means of capsid fusion protein. The incorporated nuclease could destroy viral genome (RNA or DNA) within progeny virions to reduce their infectivity. Thus intracellular expression of the fusion protein may prevent the viral de novo spread [4] . The principal feasibility of CTVI had been thoroughly investigated in the experimental system for several important viruses, such as murine leukemia virus [5, 6] , hepatitis B virus [7, 8] and human immunodeficiency virus [9, 10] , showing a promising prospect as an antiviral strategy. We have recently presented evidence that CTVI could be adapted to DV therapy and demonstrated a 12-to 60-fold reduction of infectious titer by of introduction of staphylococcal nuclease (SN) fused to dengue 2 virus capsid protein (D2C-SN).
To explore the feasibility of CTVI in a prophylactic application against DV infection, here we generated mammalian cell lines stably expressing functionally D2C-SN fusion proteins and control constructs. Those cell lines provided the experimental system for CTVI application in prophylactic model and laid the foundation for combating DV infection with this new strategy. 
Materials and Methods

Materials
Plasmids construction
Plasmids pc/D2C-SN, pc/D2C-SN* and pc/D2C were generated by transferring corresponding DNA fragments encoding the desired proteins from the constructed prokaryotic expression plasmids pLEX-CSN [11], pLEX-CSN* and pLEX-C [12] into pcDNA6/V5-His respectively as shown in Fig. 1 . The SN gene fragment was obtained from pPLC-SNwt encoding partial V8 strain SN, and the constructed pc/D2C-SN encodes D2C aa 1-99, authentic propeptide of 6 aa, and SN aa 1-149 in turn under the control of CMV promoter. The SN* gene fragment was obtained from pCS1coreSN 43/87 , and the constructed control plasmid pc/D2C-SN* with restriction sites disable was obtained as described previously [11] . SN* differed from wild SN by 2 aa substitution, changing from Glu , which did not influence the folding of SN*, but reduced its specific activity to 10 6 -fold less than that of SN. D2C gene was amplified by RT-PCR from D2-43, and constructed the control plasmid pc/D2C [12] . All plasmids were identified by restriction endonuclease digestion and DNA sequencing. Following primers were used in generating the desired DNA fragments: sense primer, 5'-GCCGAATTCGCCATGG-ATAACCAACGAAAAAAGGCGAGAA-3'; antisense primers, 5'-GATCTCGAGTTAACCTGAATCAGC-GTTGTCTTCGCTCCAAAT-3' and 5'-GATCTCGAG-TTACGCCATCACTGTTGGAATCAGCATGAT-3' (EcoRI and XhoI restriction sites in italic, Kozak sequence and stop codons underlined).
Cell culture and transfection
BHK-21 cells were cultured in DMEM medium supplemented with 10% FBS at 37 °C in 95% air + 5% CO 2 . When a confluent monolayer was formed, the cells were trypsinized, washed and resuspended in fresh DMEM medium. Approximately 5×10 5 cells were mixed with 10 µg plasmids in a 0.2-cm Gene pulser cuvette (Bio-Rad). Transfection was performed using the Gene pulser II RF module (Bio-Rad) with following parameters: total voltage, 250 V; modulation, 100%; RF frequency, 40 kHz; bust duration, 2 ms; number of burst, 5; burst interval, 1 ms. After electroporation, cells were incubated at 4 °C for 10 min and then cultured at 37 °C. Twenty-four hours post transfection 5 µg/ml blasticidin was added to the medium. The clones expressing D2C-SN and control constructs were The fragments encoding D2C, D2C-SN* and D2C-SN were respectively inserted into pcDNA6/V5-His at EcoRI-XhoI sites. D2C and SN or SN* were ligated at BamHI site and the resulting junctions between them were shown in details at the bottom of the figure. selected under pressure of blasticidin, and screened by RT-PCR and Western blot analysis.
Western blot assay
Western blot were performed as described previously [12] . In brief, samples prepared from cell lysates were separated by 12% SDS-PAGE. Following electrophoresis, proteins were transferred to a nitrocellulose membrane (Millipore) with a semidry horizontal apparatus (AMMS). The mouse monoclonal antibody Mab 8H8 was used at a dilution of 1:25 as the primary antibody, the HRP-conjugated secondary antibodies were used at dilution of 1:500, and deaminobenzidine (DAB) staining was used for color development. The molecular mass of each protein was determined using prestained protein ladder 10-180 kD. RT-PCR assay of mRNA was performed as described previously [13] .
Nuclease activity assay
In vitro DNA digestion assays were performed as followed. Approximately 1×10 6 cells were resuspended in 500 µl solution containing 40 mM Tris-HCl (pH 6.8), 100 mM NaCl, 0.1% SDS and 1% Triton X-100, and centrifuged at 1000 g for 10 min. 500 µg of ΦX174 RF I DNA and 1 mM CaCl 2 were added into the mixture and incubated at 37 °C for another 30 min. Equal aliquots were pretreated by boiling or with 0.5 M EDTA. Reaction products were electrophoresed on 0.8% agarose gels, and nuclease activities were determined by the disappearance of plasmid DNA.
Results
Experimental design
Two experimental approaches had been designed to quantitate the antiviral effect of CTVI: a prophylactic approach [ Fig. 2(A) ] which determined the inhibition ability of the antiviral constructs to subsequent virus challenge, and a therapeutic approach [ Fig. 2(B) ] which determined the effect of CTVI on reducing the reproduction of infectious virus in infected cells. In the prophylactic model, cell line stably expressing the antiviral construct D2C-SN was desirable for the subsequent D2-43 challenge and demonstration of the antiviral effects. At the same time, we constructed cell lines expressing the targeting protein D2C and a homologous fusion protein D2C-SN* as controls in parallel.
Permanent expression and identification of the antiviral constructs in BHK-21 cells
BHK-21 cells transfected with plasmid pc/D2C-SN, pc/D2C-SN* or pc/D2C were selected by 5 µg/ml blasticidin for 2 week. Thereafter the blasticidin-resistant cell clones were expandingly cultured and screened with RT-PCR and Western blot assays. The results of RT-PCR assays confirmed the transcription of mRNA expressing the corresponding D2C-SN, D2C-SN* and D2C proteins [ Fig. 3(A) ]. Transfection of plasmid pc/D2C-SN and pc/D2C-SN* resulted in the expression of a 30 kD protein that was detectable with anti-D2C antibody [ Fig. 3(B) ]. Transfection of plasmid pc/D2C resulted in the expression of an 11 kD protein, which was similar to the prokaryotic expression [12] . These results indicated BHK-21 cell lines expressing protein D2C-SN, D2C-SN* and D2C were obtained. The BHK-21 cells expressing D2C-SN, D2C-SN* and D2C were named BHK/D2C-SN, BHK/D2C-SN* and BHK/D2C respectively. There were no discernible morphological alterations between them and native BHK-21 cells (date not shown). It is therefore believed that intracellular expressed D2C-SN had no cytotoxicity on the mammalian host cells. And those blasticidin-resistant cells could be passaged every 2 to 4 day for at least 2 month. The results of indirect immunofluorescence assays (Fig. 4) showed that all the passaged engineered cells could express the desire recombinant proteins.
Nuclease activity of the intracellular expressed D2C-SN
The antiviral effect of CTVI depended on the targeting nuclease's degradability on viral nucleic acids. It was crucial that the fusion SN could be correctly folded in mammalian cells and activated by extracellular Ca
2+
. So we tested the activity of the recombinant D2C-SN nuclease using in vitro DNA digestion assay (Fig. 5) . Cell lysates prepared from BHK/D2C-SN cells could efficiently degrade ΦX174 RF I DNA. Consistent with the characteristic of SN, boiling for 5 min would boost up this effect, while treatment with EDTA resulted in the absence of nuclease activity [ Fig. 5(A) ]. Samples from BHK/D2C-SN* showed no evidence in degrading DNA as expected [ Fig. 5(B) ]. Those data provided strong evidences that the intracellular expressed D2C-fused SN was correctly folded and could be activated by environmental Ca 2+ .
Discussion
CTVI, a novel protein-based antiviral strategy, has many advantages over other antiviral strategies involving RNAbased inhibitor, like antisense RNA, ribozyme or siRNA. It is specific and efficient and could be implemented either as recombinant protein drug or for gene therapy [8] . The recent successful demonstration of transgenic mouse model based on CTVI raised the hope for farm animals suffering from viral infection [6] . With the development of gene-delivery system and correlative technology, eventual application of CTVI in combating viral diseases is coming to us.
Application of CTVI to DV may be a valuable new tool to combat this important viral infection. In this paper we fused SN gene to D2C gene at the carboxyl terminus as a CTVI effector. This orientation was chosen so that the nuclease could be inserted within the particle where it would have access to the viral RNA. Recent studies on the three dimensional structure of DV virion [14] and its capsid protein [15] provided guideline for the design of CTVI. The carboxyl terminal region of D2C is rich in positively charged amino acids such as lysine and arginine and likely interacts with RNA based on analysis of its solution structure [16, 17] . Those features sufficiently ensure that the D2C-targeted nuclease could contact the viral genome RNA directly. An ideal antiviral moiety of CTVI would be small enough to be incorporated into the nascent virions and nontoxic to host cells. SN is especially compatible for CTVI on its basic biochemical properties. It is small, and the dimensions of native SN are about 4 nm×3 nm×3 nm [18] mammalian cells and continued to hold the special promise for use in CTVI.
In summary, here we developed mammalian cell lines stably expressing D2C-SN, D2C-SN* and D2C, providing the experimental system for exploring the feasibility of CTVI in prophylactic model against DV infection. Such efforts are under way. In addition, the cell line stably expressing dengue virus capsid protein, BHK/D2C, has potential for use in analysis of RNA encapsidation and virion morphogenesis.
